title: The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Bartuzi
authors.forename: Anna
authors.initials: A
authors.lastname: Bodzenta-Łukaszyk
authors.affiliation: Department of Internal Medicine, Asthma and Allergy, University Hospital N. Barlicki, Łódź, Poland. piotr.kuna@umed.lodz.pl.
authors.forename: Piotr
authors.initials: P
authors.lastname: Kuna
authors.forename: Izabela
authors.initials: I
authors.lastname: Kupryś-Lipińska
authors.forename: Ewa
authors.initials: E
authors.lastname: Niżankowska-Mogilnicka
authors.forename: Bolesław
authors.initials: B
authors.lastname: Samoliński
mesh_terms: D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology*; D017408:Guidelines as Topic; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D000069444:Omalizumab / Q000627:therapeutic use*; D011044:Poland
chemical_list: D018927:Anti-Asthmatic Agents; D000069444:Omalizumab; D007073:Immunoglobulin E